SCHEMBL82620

SCHEMBL82620

Cc1ccc(C(=O)O)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 11/20 0.59
P4HA1 P13674 1/20 0.59
MIF P14174 1/20 0.59
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 3/20 0.57
L3MBTL1 Q9Y468 4/20 0.53
MAPK1 P28482 1/20 0.53
MAPT P10636 2/20 0.50
KMT2A Q03164 2/20 0.50
HIF1A Q16665 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
LMNA P02545 2/20 0.50
MEN1 O00255 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
PKM P14618 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
NFKB1 P19838 1/20 0.50
THPO P40225 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954297 1.00 P4HTM (0.59) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL3997737 0.98 P4HTM (0.57) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL3997731 0.98 P4HTM (0.57) P4HTMP4HA1MIFKDM4EALDH1A1
Hydrochloric Acid SCHEMBL5955817 0.98 P4HTM (0.57) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL2270351 0.98 P4HTM (0.57) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL10328698 0.85 P4HTM (0.53) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL2633139 0.84 EGLN1 (0.62) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL827893 0.82 RAB9A (0.48) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL171039 0.80 KMT2A (0.53) P4HTMKDM4EALDH1A1MAPTKMT2A
SCHEMBL9179830 0.80 RAB9A (0.47) P4HTMP4HA1MIFKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 697 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110167944-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-08-23 CN claimed
CN-118491563-A Preparation method of metal-organic framework supported iridium-based catalyst and photocatalytic CO2Reduction application 大连理工大学 2024-08-16 CN claimed
EP-3386634-B1 ION EXCHANGE RESIN FOR PRODUCING BISPHENOL, AND A METHOD FOR PRODUCING BISPHENOL USING SAID ION EXCHANGE RESIN PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) 2022-08-24 EP claimed
CN-112979672-B 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof 郑州大学 2022-03-11 CN claimed
CN-112979672-A 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof 郑州大学 2021-06-18 CN claimed
US-20180355159-A1 ION EXCHANGE RESIN FOR PRODUCING BISPHENOL, AND A METHOD FOR PRODUCING BISPHENOL USING SAID ION EXCHANGE RESIN PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) 2018-12-13 US claimed
CN-106349156-B It can be used as the pyridine -2- amides of CB2 agonist 霍夫曼-拉罗奇有限公司 2018-12-11 CN claimed
EP-3386634-A2 ION EXCHANGE RESIN FOR PRODUCING BISPHENOL, AND A METHOD FOR PRODUCING BISPHENOL USING SAID ION EXCHANGE RESIN PTT Global Chemical Public Company Limited (TH) 2018-10-17 EP claimed
CN-108602057-A Ion exchange resin for producing bis-phenol PTT全球化学公共有限公司 2018-09-28 CN claimed
EP-3112352-A1 OPIOID RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2017-01-04 EP claimed
EP-1725537-B1 NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-07-13 EP claimed
WO-2010128058-A1 DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO claimed
US-20100286158-A1 DIHYDROPYRIMIDINONES HOFFMANN-LA ROCHE, INC. 2010-11-11 US claimed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US claimed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP claimed
WO-2008013334-A1 DEFORMYLASE INHIBITOR, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION COMPRISING THE SAME PROMEDITECH INC. (KR) 2008-01-31 WO claimed
EP-0462453-B1 Preparation of reactive dyes BAYER AG (DE) 1995-04-26 EP claimed
EP-0272903-B1 PROCESS FOR PRODUCING A POLYARYLENE SULFIDE Tosoh Corporation (JP) 1993-07-21 EP claimed
US-5176718-A REACTIVE DYESTUFF PREPARATIONS CONTAINING PYRIDINE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 1993-01-05 US claimed
EP-0462453-A2 Preparation of reactive dyes BAYER AG (DE) 1991-12-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180355159-A1 ION EXCHANGE RESIN FOR PRODUCING BISPHENOL, AND A METHOD FOR PRODUCING BISPHENOL USING SAID ION EXCHANGE RESIN JMJD6, HNRNPH3, TRRAP P4HTM 39/4885P4HA1 484/4885MIF 3504/4885
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 P4HTM 240/4885P4HA1 75/4885MIF 3765/4885
US-20100286158-A1 DIHYDROPYRIMIDINONES BACE2, BACE1, PSEN2 P4HTM 902/4885P4HA1 448/4885MIF 3795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.